The effects of interferon-y (IFN-y) on a highly enriched population of granulocyte-macrophage colony-forming cells (GM-CFC) were assessed. When added with myeloid growth factors (interleukin-3 [IL-3], granulocyte-macrophage colonystimulating factor [GM-CSF], or macrophage-CSF [M-CSF]), IFN-y inhibited the formation of colonies in soft agar assays. Furthermore IFNy stimulated an increase in the ...

1. Uchida K, Nakata K, Suzuki T, et al. Granulocyte/macrophage colonystimulating factor autoantibodies and myeloid cell in healthy individuals. Blood. 2009;113(11):2547-2556. 2. St-Amour I, Laroch A, Bazin R, Lemieux R. Activation of cryptic IgG reactive with BAFF, amyloid beta peptide adn GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins. C...

Abbreviations: APC: Antigen-Presenting Cell; DCs: Dendritic Cells; RECIST: Response Evaluation Criteria in Solid Tumors; HLA: Human Leukocyte Antigen; MDSCs: Myeloid-Derived Suppressor Cells; CTLs: Cytotoxic T Cells; GM-CSF: Granulocyte-Macrophage ColonyStimulating Factor; TGF: Transforming Growth Factor; IL: Interleukin ; VEGF: Vascular Endothelial Growth Factor; PGE2: Prostaglandin E2; PD-L1:...

We performed a phase I/Il study of the administration of recombinant human granulocyte-macrophage colonystimulating factor (GM-CSF) to patients with aplastic anemia or myelodysplastic syndrome. Doses ranging from 15 to 480 .tg/m2 were administered as a one-hour or fourhour intravenous infusion daily for 7 days or as a 1 2-hour infusion for 1 4 days. Temporary improvements were seen in granulocy...

We performed a phase I/Il study of the administration of recombinant human granulocyte-macrophage colonystimulating factor (GM-CSF) to patients with aplastic anemia or myelodysplastic syndrome. Doses ranging from 15 to 480 .tg/m2 were administered as a one-hour or fourhour intravenous infusion daily for 7 days or as a 1 2-hour infusion for 1 4 days. Temporary improvements were seen in granulocy...

Neutropenia is a significant dose-limiting toxicity of cancer chemotherapy, especially in dose-intensified regimens. It is widely treated by injections of Granulocyte ColonyStimulating Factor (G-CSF). However, optimal schedules of G-CSF administration are still not determined. In order to aid in identifying more efficacious and less neutropenic treatment protocols, we studied a detailed physiol...

single-agent irinotecan. We concentrated on pretreatment levels since we wanted to determine if this “crude” measurement of glucuronidation activity could be used in clinical decision making when treating patients with irinotecan. Nonetheless, our database was limited in that we did not have routine bilirubin follow-up measurements available. We are intrigued by the results of Kramar et al, tho...

This study aimed to assess the effect of the M20 interleukin-1 (IL-I) inhibitor on normal and leukemic hematopoietic cells. The M2O-derived IL-I inhibitor was found to inhibit the growth of various hematopoietic cells. The in vitro proliferation of myeloid cell lines in serum-containing medium or proliferation of these cells induced by IL-1 in serum-free medium (measured by 3H-TdR) were inhibit...